



the **Hydroponics** company

www.thcl.com.au

16 August 2017

Chief Financial Officer and Company Secretary Appointment

COMPANY SECRETARY AND CFO APPOINTMENT

Appointment of CFO and Company Secretary

The Board is pleased to announce and welcome the appointment of Mr Jarrod White as Chief Financial Officer of the Company, effective immediately.

In addition, Mr White has also assumed the role of Company Secretary.

The Board has taken serious consideration in appointing the role of CFO recognising the importance of focusing on financial control and guidance as it invests to grow its Canadian based distribution business, its parallel investment into the domestic market, and the wider financial compliance of its listed entity requirements.

About Jarrod White

Mr White is a Chartered Accountant and founding Director of Traverse Accountants Pty Ltd, a Corporate Advisory and Chartered Accounting Firm based in Sydney.

In conjunction with his Corporate Advisory roles at Traverse, Mr. White has been appointed Company Secretary and Chief Financial Officer of several other listed entities that operate on the Australian Stock Exchange and London Stock Exchange, and has a sound knowledge of corporate governance and compliance.

Jarrod has also been an advisor to a wide range of capital raisings, IPO's and reverse takeover transactions and has a focus on working with growing Companies in the exploration, technology and biotech space.

In selecting Mr White the Board are confident that his experience and enthusiasm will assist the company in taking forward its growth objectives in the Cannabis sector.



The Hydroponics Company Limited
(ASX:THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime Street,
Sydney, NSW, Australia. 2000.

Registered Office

The Hydroponics Company Limited also advises that its registered office is now located at Suite 305, Level 3, 35 Lime Street, Sydney NSW 2000 with effect from the date of this announcement.

Resignation of Company Secretary

The Hydroponics Company Limited (ASX: THC or the Company) announces that Mr Henry Kinstlinger has ceased as Company Secretary, effective August 2017.

The Board wishes to thank Mr Kinstlinger for his service and contribution to the Company over the past year as Company Secretary, and particularly for his efforts in the IPO and listing process completed in May 2017.

For further information, please contact:



Jarrold White
Chief Financial Officer

Alan Beasley
Chairman

The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177



Michael Lovesey
Director Corporate Media Relations

MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street
Sydney, NSW 2000 Australia

P: +61 2 9251 7177

M: +61 449 607 636

E: michaell@mmlrcorporate.com

About The Hydroponics Company www.thcl.com.au

The Hydroponics Company (ASX: THC) is at the forefront of developing a leading, diversified worldwide cannabis business, focused on three core business units: Development and delivery of medicinal cannabis, manufacturing and distribution of hydroponics equipment, materials and nutrients, and large scale hydroponic greenhouse design and construction. With +17 years of Cannabis sativa breeding, variety selection and growth management, THC is actively developing plant breeding technology to target multiple markets for high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

About Canndeo Limited www.canndeo.com

Canndeo is a wholly-owned subsidiary of The Hydroponics Company (ASX: THC) that operates under a pharmaceutical model with a focus on the end-to-end supply of medicinal cannabis products. The Company has leading expertise in breeding, growth and extraction capability with a focus on the rapid introduction of medicinal cannabis products. A Medicinal Cannabis Research License was granted to Canndeo on 6 July 2017. Canndeo leverages +17 years of Cannabis sativa breeding, variety selection and growth management. Canndeo will target multiple medical markets with high purity cannabidiol (CBD), a new class of medicinal product that can be used to target dementia, epilepsy and other neurological disorders.

Disclaimer Regarding Forward Looking Statements

This announcement contains forward-looking statements which are identified by italic words that involve risks and uncertainties. Indications of, and guidelines or outlook on, future earnings, distributions or financial position or performance and targets, estimates and assumptions in respect of production, prices, operating costs, results, capital expenditures, reserves and resources are also forward-looking statements. These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions and estimates regarding future events and actions that, while considered reasonable as at the date of this announcement and are expected to take place, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the directors and management. We cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are subject to various risk factors that could cause actual events or results to differ materially from the events or results estimated, expressed or anticipated in these statements.